Immutep: Reveals encouraging interim results from phase two TACTI-002 study
Immutep (IMM) has released further interim data from its Phase II TACTI-002 Study in patients with lung, head, and neck cancers
The study...
© 2026 FintechInshorts. All Rights Reserved.

